Conversion lung transplant patients from Prograf to Advagraf or Envarsus

Pharmacokinetic Study of Conversion Between 2 Formulations of Tacrolimus in Stable Lung Transplant Patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12622000664741

Enrollment

Registered

2022-05-05

Start date

2021-01-01

Completion date

Unknown

Last updated

2023-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

30 days after lung transplantation patients with tacrolimus (Prograf) will be transfered randomisation to once daily tacrolimus (Advagraf, Envarsus) Which product will be better evaluated Advagraf or Envarsus

Interventions

tacrolimus: dose administered 1 mg once daily the total duration of administration 3 years the mode of administration tablet prolonged release formulation (Advagraf, Envarsus)

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

minimum age 18 years, 30 days after lung transplant, need to be prescribed tacrolimus (Advagraf, Envarsus) once daily for 30 days after lung transplant

Exclusion criteria

refusal to participate in the study

Outcome results